Related Experiment Video

Updated: Apr 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Reply to: "To target or not to target viral antigens in HBV related HCC?"

Waseem Qasim1, Maurizia Brunetto2, Adam J Gehring3

  • 1Institute of Child Health & Great Ormond Street Hospital, University College London, London, UK.

Journal of Hepatology
|February 26, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Related Experiment Videos

Last Updated: Apr 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Related Concept Videos

Hepatitis01:25

Hepatitis

63
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63

Articles linked to this work by shared authors, journal, and citation graph.

Sex-specific trajectories of nonlinear immune aging at single-cell level.

Nature communications·2026

Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion.

Journal of immunology (Baltimore, Md. : 1950)·2026

Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.

Antiviral research·2026

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.

Nature cancer·2026

Combined HDV RNA and anti-HDV measurement for the management of HBV/HDV coinfection.

Hepatology (Baltimore, Md.)·2026

Persistent loss of intrahepatic IFN-γ in HBV is linked to selective impairment of liver-resident CXCR6+NK cells despite long-term NUC therapy.

JHEP reports : innovation in hepatology·2026

EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.

Journal of hepatology·2026

Restoration of aged liver regeneration by youthful systemic factors via LTβ-driven hepatocyte reprogramming.

Journal of hepatology·2026

Systemic therapy for HCC: Doublets, triplets and beyond.

Journal of hepatology·2026

Integrating systemic therapy in the earlier stages of liver cancer.

Journal of hepatology·2026

The use of locoregional therapies in cholangiocarcinoma.

Journal of hepatology·2026

Liver transplantation for primary liver cancers in the era of transplant oncology.

Journal of hepatology·2026

Genetic and hemostatic characterization of PAI-1 deficiency and isolated hyperfibrinolysis: data from the RBiN study.

Research and practice in thrombosis and haemostasis·2026

A miniaturized chemiluminescent thrombin generation assay to assess the effect of APCC in persons with hemophilia A with inhibitors: an observational study.

Research and practice in thrombosis and haemostasis·2026

Artificial intelligence prediction of therapy response in newly diagnosed adult severe primary immune thrombocytopenia.

Research and practice in thrombosis and haemostasis·2026

Hematuria in children: causes and evaluation.

Childhood kidney diseases·2026

Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies.

Childhood kidney diseases·2026

Refractory perirenal effusion in a pediatric patient with antithrombin III deficiency and KILT syndrome: a case report.

Childhood kidney diseases·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us